Vitamin D3 Mega-dose Treatment to Reduce Moderate to Severe Chronic Pain in Adults on Hemodialysis

What this Trial Is About

Researchers are evaluating the effects of high-dose vitamin D3 supplementation on moderate to severe chronic pain in patients undergoing hemodialysis who have elevated parathyroid hormone levels. This study is designed as a single-center, parallel, double-blind randomized controlled trial involving 120 eligible adults. The goal is to see if multiple mega doses of vitamin D3 can help reduce chronic pain measured by the Visual Analogue Scale VAS. Participants will be randomly assigned to receive either oral vitamin D3 supplementation at a dose of 576,000 IU once a week for four weeks, totaling 2,304,000 IU, or a placebo given on the same schedule. The study lasts for four weeks of treatment, with the vitamin D3 or placebo taken weekly. During the trial, participants will have their pain severity assessed at baseline and weekly for five weeks using the VAS. Blood tests will measure serum levels of 25OHD, calcium, phosphorus, parathyroid hormone PTH, and C-reactive protein at the start and after supplementation. Researchers will monitor these measures to evaluate the supplementations impact on pain and related biochemical markers throughout the study period.

Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients